Compare ARK Genomic Revolution ETF (ARKG) vs Zscaler Inc (ZS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Zscaler Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.21, while Zscaler Inc trades at $139.5 (market cap $22.52B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | ZS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $336.27 |
52-Week Low | $23.09 | $118.05 |
Market Cap | — | $22.52B |
Enterprise Value | — | $20.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Zscaler (ZS) trades at $139.27, down 5.34% on the day, amid mixed signals. The stock shows strong revenue growth with 2025 revenue reaching $2.67 billion and consistent quarterly EPS beats, but remains unprofitable with a net income margin of -2.44%. Technical indicators are bullish on moving averages but show overbought RSI levels. Recent news highlights class action investigations and AI infrastructure cost pressures, yet analyst sentiment remains overwhelmingly positive with a consensus price target of $192.64.
The outlook for ZS is cautiously optimistic driven by robust cybersecurity demand and AI security traction, but risks include profitability challenges, rising costs, and legal scrutiny. Wall Street maintains a strong buy consensus (79% buy ratings), suggesting significant upside potential if execution improves and margins stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
